Stay updated with breaking news from Liver Tumor Program. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Amit Singal, MD, medical director of the Liver Tumor Program at UT Southwestern Medical Center, discussed the current outlook for patients with hepatocellular carcinoma (HCC) and how to choose between therapies.
Amit Singal, MD, medical director of the Liver Tumor Program at UT Southwestern Medical Center, discussed how the etiologies of hepatocellular carcinoma (HCC) and underlying liver function impact treatment approach.
A drug that targets a protein known as phosphatidylserine boosted the response rate for hepatocellular carcinoma (HCC) patients receiving immunotherapy without
A drug that targets a protein known as phosphatidylserine boosted the response rate for hepatocellular carcinoma (HCC) patients receiving immunotherapy without
Amit Singal, MD, medical director of the UT Southwestern Medical Center Liver Tumor Program, discusses populations at the highest risk of hepatocellular carcinoma (HCC), when screening is needed, and key tools in HCC surveillance and screening.